Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAWN-303: INCB161734 plus chemotherapy versus placebo plus chemotherapy in first-line KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma
NL-OMON61319Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Sep 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing INCB161734 plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoints: Overall survival, Progression-free survival by blinded independent central review and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
INCB161734
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON61319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61319.